71 related articles for article (PubMed ID: 8648821)
21. Establishment of doxorubicin-resistant human bladder cancer cell line (BUI-87/ADMR) and its mechanism of multidrug resistance.
Guo H; Lu G; Xiong X; Dong J; Liu S
Chin Med J (Engl); 1997 Mar; 110(3):167-72. PubMed ID: 9594332
[TBL] [Abstract][Full Text] [Related]
22. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
23. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
24. Metallothionein gene expression in bladder cancer exposed to cisplatin.
Wood DP; Klein E; Fair WR; Chaganti RS
Mod Pathol; 1993 Jan; 6(1):33-5. PubMed ID: 8426855
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
26. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
27. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.
Aaltonen V; Boström PJ; Söderström KO; Hirvonen O; Tuukkanen J; Nurmi M; Laato M; Peltonen J
Am J Pathol; 1999 Mar; 154(3):755-65. PubMed ID: 10079253
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma.
Shang C; Guo Y; Zhang H; Xue YX
Cancer Chemother Pharmacol; 2016 Mar; 77(3):507-13. PubMed ID: 26781446
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen enhances the chemosensitivity of bladder carcinoma cells.
Pu YS; Hsieh TS; Tsai TC; Cheng AL; Hsieh CY; Su IJ; Lai MK
J Urol; 1995 Aug; 154(2 Pt 1):601-5. PubMed ID: 7609145
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of induction of MDR1 gene expression by anticancer chemotherapy in bladder cancer].
Nezasa S; Fujihiro S; Deguchi T; Kawada Y; Kawamoto S; Tamaki M; Yamada S; Okano M
Hinyokika Kiyo; 1997 Sep; 43(9):629-36. PubMed ID: 9365841
[TBL] [Abstract][Full Text] [Related]
31. Establishment and characterization of two human bladder cancer cell lines.
Naito S; Kotoh S; Koga H; Hasegawa S; Yamasaki T; Noma H; Kumazawa J
Hum Cell; 1996 Mar; 9(1):49-56. PubMed ID: 9183630
[TBL] [Abstract][Full Text] [Related]
32. MDR-1 expression in metastatic malignant melanoma.
Levine EA; Holzmayer TA; Roninson IB; Das Gupta TK
J Surg Res; 1993 Jun; 54(6):621-4. PubMed ID: 8105147
[TBL] [Abstract][Full Text] [Related]
33. Characterization and modulation of transitional cell carcinoma cell lines with acquired multidrug resistance.
Yu DS; Chang SY; Ma CP
Br J Urol; 1998 Feb; 81(2):234-40. PubMed ID: 9488065
[TBL] [Abstract][Full Text] [Related]
34. The expression of oncoproteins in transitional cell carcinoma: its correlation with pathological behavior, cell cycle and drug resistance.
Yu DS; Chang SY
Urol Int; 2002; 69(1):46-50. PubMed ID: 12119439
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder: implications and applications.
Benson MC; Giella J; Whang IS; Buttyan R; Hensle TW; Karp F; Olsson CA
J Urol; 1991 Oct; 146(4):982-6; discussion 986-7. PubMed ID: 1680203
[TBL] [Abstract][Full Text] [Related]
36. [Expression and clinical significance of mdr-1 gene in lymphoma].
Tian WH; Feng HL; Gao JS; Jiang WQ
Ai Zheng; 2002 Aug; 21(8):910-3. PubMed ID: 12478906
[TBL] [Abstract][Full Text] [Related]
37. The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation.
Adshead JM; Ogden CW; Penny MA; Stuart ET; Kessling AM
BJU Int; 1999 Jun; 83(9):1039-44. PubMed ID: 10368252
[TBL] [Abstract][Full Text] [Related]
38. Molecular cloning and expression of uroplakins in transitional cell carcinoma.
Yuasa T; Yoshiki T; Isono T; Tanaka T; Okada Y
Adv Exp Med Biol; 2003; 539(Pt A):33-46. PubMed ID: 15088894
[TBL] [Abstract][Full Text] [Related]
39. Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
Packeiser EM; Hewicker-Trautwein M; Thiemeyer H; Mohr A; Junginger J; Schille JT; Murua Escobar H; Nolte I
PLoS One; 2020; 15(3):e0230272. PubMed ID: 32168360
[TBL] [Abstract][Full Text] [Related]
40. Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract.
Naito S; Sakamoto N; Kotoh S; Goto K; Matsumoto T; Kumazawa J
Eur Urol; 1992; 22(2):158-62. PubMed ID: 1362155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
